Lucknow: As Uttar Pradesh intensifies efforts to achieve its ambitious $1 trillion economy target, the Yogi Adityanath government is steadily expanding its focus beyond traditional manufacturing and services by aggressively promoting the pharmaceutical and healthcare manufacturing sector as a major economic growth driver.
In a significant step towards strengthening this ecosystem, the state recently organised the Pharma Conclave, aimed at attracting investments, boosting pharmaceutical manufacturing and positioning Uttar Pradesh as a leading healthcare production hub in the country. The conclave witnessed strong industry participation and highlighted the government’s long-term strategy to create a future-ready pharma ecosystem backed by industrial infrastructure, policy incentives and export-oriented manufacturing.
Reflecting the growing confidence of the pharmaceutical industry in Uttar Pradesh, Lucknow-based Jedux Parenterals Pvt Ltd has emerged as one of India’s leading intravenous (IV) fluid manufacturers. Established across nearly six acres with an investment of around ₹105 crore, the company specializes in advanced IV fluid solutions and large volume parenterals catering to hospitals, clinics and healthcare institutions in India and overseas markets.
Since commencing commercial production in 2019, Jedux has rapidly scaled operations and currently manufactures nearly four lakh bottles per day. The company produces a diverse portfolio of more than 70 pharmaceutical and IV fluid products and exports to over 10 international markets. Industry observers consider Jedux among the top five IV fluid manufacturers in India, underlining Uttar Pradesh’s rising capabilities in pharmaceutical manufacturing and global healthcare supply chains.
Apart from strengthening industrial growth, the company is also contributing significantly to employment generation in the state. Jedux currently employs more than 250 people, with women accounting for over 70 percent of its workforce, highlighting the growing role of women in Uttar Pradesh’s industrial and healthcare manufacturing sectors.
To further accelerate sectoral growth, the state government is rapidly developing dedicated pharmaceutical infrastructure under UPSIDA. The Lalitpur Pharma Park is emerging as a major pharma investment destination, with Phase I spread across 352.91 acres for formulation units, bulk drugs and common infrastructure facilities. Phase II, covering 1,465 acres, is also under development and an Expression of Interest (EOI) has already been floated. Backed by an overall land bank of nearly 8,000 acres, Uttar Pradesh is strategically positioning itself among India’s largest integrated pharma ecosystems.
Further strengthening this vision, the Yamuna Expressway Industrial Development Authority is developing a 350-acre Medical Device Park in Sector-28 equipped with advanced ASCA-certified testing laboratories to reduce dependence on overseas testing facilities. Additionally, a 250-acre Pharma Formulation Park near the Noida International Airport is planned in Sector-7, offering strong export connectivity and reinforcing Uttar Pradesh’s emergence as North India’s key healthcare manufacturing hub.
A major highlight of the Pharma Conclave was the signing of investment intents worth nearly ₹10,000 crore through 11 MoUs in pharmaceuticals and medical devices. These commitments are expected to expand manufacturing capacity, strengthen healthcare supply chains, and generate large-scale employment, giving fresh momentum to Uttar Pradesh’s rapidly growing pharmaceutical sector.
